Cancer Treatment Centers of America together with NantHealth and Allscripts have begun rolling out of a program that will see Eviti have access to workflows in the Allscripts EHR. Eviti is a clinical decision support system owned by NantHealth. This system is meant to stop any interference with the clinical workflow of the physician. The support system has a direct interface, which has data and information on cancer care. This data is collected from more than a hundred cancer-care institutions spread across America.
Eviti is supposed to clear any uncertainty among clinicians when dealing with cancer patients. This will be possible since it will be regularly updated with new information and research. The patients are able to choose the treatment options they feel are safe for them. The treatment platform gives comparisons on the various treatment methods available in order to give the patient the best deal.
The clinical support system will go a long way in bettering the quality and efficiency of cancer care. It will also help patients get approval from their health insurance providers, as the comparison of different treatment options will be available. The data in the system will be effective as it is comprised of more than 2700 cancer treatment options.
Cancer Treatment Centers of America has its headquarters at Boca Raton, Florida. It was, however, initially headquartered in Schaumburg, Illinois before it was relocated in 2015. It has a network of five cancer hospitals in the United States. The hospitals are located in Philadelphia, Pennsylvania, Georgia, Chicago, Phoenix, and Arizona.
CTCA was founded by Richard J Stephenson in 1988. The inspiration behind it was the death of her mother who succumbed to cancer. Richard was dissatisfied with the treatment his mother received while she was ailing, and he decided to come up with a better and efficient technology. Each of the CTCA’s hospitals has employed cancer experts as well as the use of the latest cancer treatment technologies. Some of the treatment options include surgery, immunotherapy, and chemotherapy.
For more information follow CTCA on Twitter.